BSE · 531146 · Pharmaceuticals
Medicamen Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹47 Cr with net profit ₹2 Cr — a 5.05% net margin, versus 5.77% the period before.
Shareholding
As of 2026-10-31
- Promoter42.57%
- Public53.08%
- FII4.35%
- DII0%
11,662 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.16× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #21 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
| Medicamen Biotech Ltd.(this company) | ₹398 Cr | 36.71 | 1.35 | 4.11% | 5.51% |
AI analysis
AI-generated · google/gemini-2.5-flashMedicamen Biotech Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 335 Cr. The company reported a profit margin of 5.5% and a dividend yield of 40%. The debt-to-equity ratio stands at 0.15.
Positives
- +The company has a high dividend yield of 40%.
- +The return on equity (ROE) is significantly high at 349.89%.
- +The debt-to-equity ratio is low at 0.15.
- +There is no promoter share pledge recorded.
Negatives
- −Revenue growth for the full year was negative at -9.35%.
- −The company is currently under LT-ASM, indicating regulatory surveillance.
- −The Return on Capital Employed (ROCE) is relatively low at 4.7882%.
- −Promoter holding decreased from 40.4569% in the current period to 34.7% in Mar 2017.
- −No annual revenue or profit figures were provided for the most recent financial year.
Financial Performance
The company’s revenue growth was -9.35%. Quarterly revenue in March 2026 was Rs 60.65 Cr with a net profit of Rs 3.86 Cr. In December 2025, revenue was Rs 46.91 Cr with a net profit of Rs 2.19 Cr. Net profit in March 2025 was Rs 2.42 Cr on revenue of Rs 29.61 Cr.
Profitability & Returns
Medicamen Biotech Ltd. has a profit margin of 5.5%. The return on equity (ROE) is 349.89%, while the return on capital employed (ROCE) is 4.7882%. The earnings per share (EPS) is Rs 7.11.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.15. The book value per share is Rs 203.17. No figures for total assets or liabilities were provided.
Ownership & Pledges
As of June 30, 2026, promoter holding was 40.4569%. Public shareholding was 59.069%, with DIIs holding 0.4032% and FIIs holding 0.0709%. Total institutional holding was 0.4741%. There is no promoter share pledge recorded.
Regulatory & Surveillance
Medicamen Biotech Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) · ASM 1, which indicates increased regulatory monitoring.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Oct 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.